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ABSTRACT 
Background: The extended spectrum beta lactamases producing bacteria are bacteria of great concern among 
Gram negative bacilli. Escherichia coli stand out as major carrier of this enzyme. The appropriate control of this 
resistance pattern depends on using the antimicrobial regimen of best choice. Therefore the value of the 
susceptibility profile of organism harboring this enzyme cannot be overemphasized. 
Objectives: To determine the antimicrobial susceptibility of extended spectrum beta lactamases (ESBL) producing 
and the non-ESBL producing strains of Escherichia coli from clinical isolates of Escherichia coli in University of 
Maiduguri Teaching Hospital. 
Methodology: Confirmed variants of Escherichia coli were screened and confirmed for ESBL possession. 
Subsequently, modified Kirby Bauer method was utilized to test for antibiotic susceptibility using the 
commercially available Oxoid single disc for some major antibiotics. 
Results: A total of 172 strains of Escherichia coli were identified during the study period. Out of this number; 131 
were identified as ESBL positive while a total of 41 were ESBL negative. The highest sensitivity for both the ESBL 
positive and ESBL negative strains of Escherichia coli was observed with Imipenem followed closely by 
Gentamicin. 
Conclusion: The study reveals narrow choice of antibiotics for the ESBL positive isolates of Escherichia coli 
although Imipenem antibiotic still retains its sensitivity. 
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RESUME : 
Contexte : Les bêta lactamases à spectre étendu produisant bactérie sont des bactéries de grande inquiétude parmi les bacilles à 
Gram négatif. Escherichia coli se démarque en tant que porteur de cette enzyme. Le contrôle approprié de cette modèle de 
résistancedépend d’usage de régime antimicrobien de la meilleur choix. Donc, la valeur du profil de sensibilité d’organisme 
hébergeant cette enzyme ne peut êtresoulignée. 
 
Objectifs : Déterminer la sensibilitéantimicrobienne des bêta lactamases à spectre étendu(BLSE) souches productrices et non 
productrices de BLSE d’Escherichia coli des isolats cliniques d’Escherichia colià l’Universitéhôpital d’enseignement, Maiduguri. 
 
Méthodologie : Des variantesconfirmées d’Escherichia coli ont été examinées et confirmées pour la possession de BLSE. Ensuite, 
méthodeKirby Bauer modifiée a été utilisée pour analyser la sensibilité antibiotique en utilisant le disque unique Oxoid 
disponible dans le commerce pour des antibiotiques majeurs. 
 
Résultats : Un total de 172 souches d’Escherichia coli ont été identifiées au cours de la période d’étude. Sur ce nombre,131 
étaientidentifiées en tant que BLSE positifs alors qu’un total de 41étaient BLSE négatifs. La plus haute sensibilité pour les 
souches BLSE positifs et les souches BLSE négatifsd’Escherichia coli était observées avec imipenème suivi étroitement par 
Gentamicine. 
 
Conclusion : L’étuderévèle un choix limité des antibiotiques pour les isolats BLSEpositifs d’Escherichia coli bien que 
l’antibiotique imipenème conserve encore sa sensibilité. 
 
Mots – clés : Céphalosporines, Résistance, Maiduguri,Nigeria. 
 
INTRODUCTION 
Extended spectrum beta lactamases are plasmid 
mediated enzymes that are capable of conferring 
bacterial resistance to the penicillins, first, second and 
third generation cephalosporins and aztreonam.(1) 
They do this by hydrolysis of these antibiotics but 
they are inhibited in vitro by beta lactamase inhibitors 
such as clavulanic acid.(1) The beta lactams are the 
most commonly used antimicrobial drugs accounting 
for almost 50% of antibiotic use.(2)  
ESBLs have been reported worldwide in many 
different genera of Enterobacteriaceae and Pseudomonas 
aeruginosa.(3) However, they are more common in 
Klebsiella pneumoniae and Escherichia coli.(4) 
Carbapenems are the drugs of first choice in most 
infections due to ESBL producers but they need to be 
used judiciously to remain efficacious. (5)  
This study aims to determine the antimicrobial 
susceptibility pattern of the ESBL and the non ESBL 
producing strains of Escherichia coli in our locality 
with the aim of providing a rationale antibiotic 
profile. 
METHODOLOGY 
Study Area: The study was carried out in the 
department of Medical Microbiology and 
Parasitology University of Maiduguri Teaching 
hospital from January to June, 2014.  
Study Design: Descriptive, Observational and Cross-
sectional in design 
 
 
Sample Size: A total of 172 strains of Escherichia coli 
were isolated during the study period 
Clinical Specimen: The isolates were obtained from 
the following specimens; wound swabs, wound 
biopsies, aspirates, urine, cerebrospinal fluid, blood 
culture, sputum, ear swabs and eye swabs that were 
submitted to Medical Microbiology Department of 
University of Maiduguri Teaching Hospital (UMTH) 
for routine analysis. 
Sampling Method: Non-probability, convenient 
sampling was used. All specimens that yielded the 
growth of Enterobacteriaceae during the study period 
were utilized. 
Bacterial Culture and Preliminary Identification: 
The specimens were inoculated on MacConkey agar. 
They were then incubated at 18-24 hours under 
aerobic atmosphere at 37 ºC. Any isolate with the 
typical morphology of Escherichia coli is picked for 
additional studies. The morphology of Escherichia coli 
on MacConkey is that of a lactose fermenter; 
producing pink colored colonies that are 1-4 mm in 
diameter and slightly mucoid.(6) Gram staining and 
motility testing was done. Escherichia coli are Gram 
negative rods and motile. 
Bacterial Confirmation: Suspected isolates of 
Escherichia coli were confirmed by the Microbact Gram 
negative identification system 24E TM (Oxoid) 
according to the manufacturer’s instructions. 
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ESBL Screening: Isolates were screened for ESBL 
production by using disc diffusion of cefotaxime 
(CTX) and ceftazidime (CAZ) placed on inoculated 
plates containing Muller Hinton agar according to 
Clinical and Laboratory Standard Institutes (CLSI) 
recommendations. (7)  
ESBL Confirmation: Double disk synergy test was 
performed by placing ceftazidime (30 µg) and 
cefotaxime (30 µg)  at a distance of 20 mm (centre to 
centre) from a disc containing amoxicillin (20 µg) plus 
clavulanate (10 µg); (augmentin; 30 µg ).  Positivity for 
ESBL production was interpreted if there is a ≥ 5mm 
diameter for either antimicrobial agent tested in 
combination with clavulanic versus its diameter when 
tested alone as recommended by CLSI. (7)  
Susceptibility Testing: The modified Kirby Bauer 
method was utilized. Antibiotic sensitivity testing 
was done using the commercially available Oxoid 
single disc comprising of ampicillin(10µg), 
amoxicillin/ clavulanic acid(10/20 µg), 
ciprofloxacin(5µg), trimethoprim/ 
sulphamethoxazole(1.25/23.75µg), gentamicin(10µg), 
ceftazidime(30µg), cefotaxime(30µg) and 
imipenem(10µg). The test was carried out on Mueller 
Hinton agar according to CLSI guidelines.(7) 
Ethical Consideration: The study protocol was 
reviewed and approved by the Ethical Review 
Committee of UMTH 
Data Analysis: Data analysis was carried out using 
the Microsoft Excel, computer software. 
RESULTS 
A total of 172 isolates of Escherichia coli were 
identified during the study period. Out of this 
number 60 were screened as ESBL positive while 112 
were screened as ESBL negative. However, following 
the confirmatory testing; 41 were identified as ESBL 
producers while 131 were identified as ESBL 
negative.  The distribution of the various isolates 
based on the specimen is as shown in Table 1. 
The antimicrobial susceptibility profile of the 131 
ESBL negative Escherichia coli were as shown in Figure 
1.  
All the 131(100%) isolates were sensitive to imipenem. 
Gentamicin was the second most sensitive 
antimicrobial agent with 113(86%). The highest 
resistance of 71(54%) was observed with ampicillin, 
followed by ciprofloxacin with 52(40%).    
The antimicrobial susceptibility profile of the 41 ESBL 
positive Escherichia coli were as shown in Figure 2. 
The highest sensitivity of 37(90%) was observed with 
imipenem, followed by gentamicin with 27(66%). 
However, the highest resistance was observed with 
ceftazidime and cefotaxime with 41(100%) and 
35(85%) respectively. 
 
TABLE 1: DISTRIBUTION OF THE 172 ISOLATES OF 
ESCHERICHIA COLI BASED ON SPECIMEN ISOLATED 
Specimen     No       %                
Swabs          39       22.7 
Urine            68       39.5 
Blood            18       10.5 
CSF               16       09.3 
Pus                31       18.0 
Total             72       100 
 
FIGURE 1: SUSCEPTIBILITY PATTERN OF ESBL 
NEGATIVE STRAINS OF ESCHERICHIA COLI (N=131) 
 
Legend: Amoxi/Clav = Amoxicillin/Clavulanic acid; 
Trimet/Sulpa = Trimethoprim/Sulphamethoxazole 



























































































































FIGURE 2: SUSCEPTIBILITY PATTERN OF ESBL 
POSITIVE STRAINS OF ESCHERICHIA COLI (N=41) 
 
Legend: Amoxi/Clav = Amoxicillin/Clavulanic acid; 
Trimet/Sulpa = Trimethoprim/Sulphamethoxazole 
S = Sensitive; I = Intermediate; R = Resistant 
 
DISCUSSION 
This study recorded a low resistance to imipenem but 
a high resistance to ampicillin and ciprofloxacin for 
the ESBL negative strains of Escherichia coli. This 
implies that imipenem are effective for the treatment 
of the ESBL positive strains but ampicillin and 
ciprofolaxacin are ineffective and may result in 
treatment failure if used. Nwadioha and colleagues 
reported a similar finding, (8) although it’s in contrast 
to the work of Olanitola where ESBL negative 
Escherichia coli were found to have low resistance to 
ciprofloxacin and amikacin. (9)  
This study recorded a low resistance of imipenem, 
gentamicin and ciprofloxacin but a high resistance of 
ceftazidime, cefotaxime and ampicillin for the ESBL 
positive strains of Escherichia coli. The finding is in 
agreement with the work of Kadar et al (10) in 2005, 
where 89% of the ESBL producers were susceptible to 
imipenem and meropenem. Even though, a different 
finding was noted by Okesola and Oni (11) in a study, 
to determine the susceptibility of carbapenems 
(imipenem and meropenem) and amikacin against the 
ESBL-producing Klebsiella isolates. The finding of a 
high sensitivity to imipenem is likely due to the fact 
that this antibiotic is expensive and not commonly 
prescribed hence selection for resistance is minimal 
compared to the other readily available 
antimicrobials. The clinical significance of the finding 
is that ampicillin and cephalosporins are not likely to 
be successful in treating the infection caused by ESBL 
positive isolates of Escherichia coli. However, 
trimethoprim/sulphamethoxazole can be used with 
caution when treating empirically for the urinary 
isolates of Escherichia coli as it has a relative sensitivity 
for ESBL positive Escherichia coli from this study.  
Carbapenem (imipenem) class antibiotic was the most 
reliably effective empirical therapies for infection 
with these organisms, even though worrisome fact of 
resistance to imipenem of 9.8% (4/41) for ESBL 
positive Escherichia coli was observed.  
The antibiotic susceptibility of the ESBL positive 
isolates of Escherichia coli revealed a limited group of 
effective antibiotics for the treatment of infections 
caused by this organism. The multi drug resistance 
observed in ESBL positive isolates might reflect the 
fact that, ESBLs have been associated with co-
resistance to other agents including trimethoprim-
sulphamethoxazole, gentamicin and ciprofloxacin. 
(12)   
Cephalosporins, frequently used against 
Enterobacteriaceae, were widely recommended and 
abused in the past decade. (13) This study revealed 
the already documented resistance of ESBLs to 
cephalosporins in addition to likely quinolones co-
resistance. This happens because some of the patients 
had exposure to both cephalosporins and quinolones 
or both resistances could be simultaneously adopted 
by plasmid-mediated mechanisms. (14) Therefore 
these agents cannot be use for empirical treatment of 
infections due to ESBLs producing organisms. 
CONCLUSION: The study revealed a pan resistance 
of ESBL positive Escherichia coli isolates to the beta 
lactam agents in addition to the likely quinolone co-
resistance. However, Imipenem retain its sensitivity 
for the ESBL positive isolates. In view of this drug 
resistance the practice of routine ESBL testing along 
with the use of the appropriate antibiotic following a 
conventional antibiogram would be useful for all 
cases which will help in the proper treatment of the 
patient and also prevent further development of 
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